Kazuhide Nakatomi - Hisamitsu Pharmaceutical President, COO and Executive VP
| HTSUFDelisted Stock | USD 30.31 0.00 0.00% |
President
Mr. Kazuhide Nakatomi was serving as President, Chief Operating Officer and Representative Director of Hisamitsu Pharmaceutical Co., Inc. since May 2015. He joined the Company in April 1999. His previous titles include Vice President, Senior Managing Director, Managing Director and Manager of 2nd Tokyo Office in the Company. since 2015.
| Age | 51 |
| Tenure | 9 years |
| Phone | 81 3 5293 1720 |
| Web | https://www.hisamitsu.co.jp |
Hisamitsu Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0212 % which means that it generated a profit of $0.0212 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0504 %, meaning that it generated $0.0504 on every $100 dollars invested by stockholders. Hisamitsu Pharmaceutical's management efficiency ratios could be used to measure how well Hisamitsu Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Hisamitsu Pharmaceutical Co has accumulated 219 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Hisamitsu Pharmaceutical has a current ratio of 4.37, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Hisamitsu Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Hisamitsu Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hisamitsu Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hisamitsu to invest in growth at high rates of return. When we think about Hisamitsu Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | PRESIDENT Age | ||
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Christina Ackermann | Bausch Health Companies | 55 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Scott Dreyer | Collegium Pharmaceutical | 52 | |
| Paul Herendeen | Bausch Health Companies | 65 | |
| William PPool | Prestige Brand Holdings | 59 | |
| Masato Iwasaki | Takeda Pharmaceutical Co | 61 | |
| Giles Platford | Takeda Pharmaceutical Co | 46 | |
| Andrew Plump | Takeda Pharmaceutical Co | 59 | |
| Joseph Gordon | Bausch Health Companies | 56 | |
Management Performance
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 |
Hisamitsu Pharmaceutical Leadership Team
Elected by the shareholders, the Hisamitsu Pharmaceutical's board of directors comprises two types of representatives: Hisamitsu Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hisamitsu. The board's role is to monitor Hisamitsu Pharmaceutical's management team and ensure that shareholders' interests are well served. Hisamitsu Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hisamitsu Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kyu Saito, Executive Officer, Director of International Business, Chairman of Subsidiaries, Director | ||
| Shinichiro Takao, General Manager of IR Department, Treasurer and Director | ||
| Mitsutoshi Tsuruta, Ex Division | ||
| Masaya Okuno, OTC Division | ||
| Kazuhide Nakatomi, President, COO and Executive VP | ||
| Koji Takiyama, Executive Officer, Manager of President's Office | ||
| Kosuke Sugiyama, Senior Managing Director, Executive Officer, Director of Human Resource | ||
| Shinichi Murayama, Executive Officer, Manager of President's Office in Kyushu Headquarters, Director | ||
| Nobuo Tsutsumi, Executive Officer, Director of Legal Affairs, Director | ||
| Mitsumasa Kabashima, Pres Ltd |
Hisamitsu Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hisamitsu Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.15 B | |||
| Shares Outstanding | 79.53 M | |||
| Shares Owned By Insiders | 26.45 % | |||
| Shares Owned By Institutions | 35.26 % | |||
| Price To Earning | 22.53 X | |||
| Price To Book | 0.97 X |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Hisamitsu Pink Sheet
If you are still planning to invest in Hisamitsu Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hisamitsu Pharmaceutical's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |